Short- and medium-term increase of CA125 in peritoneal effluent using a neutral-pH solution

Peritoneal Dialysis International

Volumn 23, Issue 4, 2003, Pages 375-380

  García, Héctor ^a   Hernández Jaras, Julio ^a   del Carmen Cruz, María ^a   Agramunt, Isabel ^a   Calvo, Consuelo ^a   Cerrillo, Vicente ^a  

^a HOSPITAL GENERAL DE CASTELLÓN   (Spain)

Author keywords

Bicarbonate; CA125 kinetics; Months on PD; Neutral pH; Peritoneal transport; Peritonitis; Ultrafiltration

Indexed keywords

BICARBONATE; CA 125 ANTIGEN; LACTIC ACID; PERITONEAL DIALYSIS FLUID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIALYSATE; EFFLUENT; FEMALE; HUMAN; MALE; MESOTHELIUM CELL; PERITONITIS; PH; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; AGED; ASCITIC FLUID; BICARBONATES; CA-125 ANTIGEN; CROSS-OVER STUDIES; DIALYSIS SOLUTIONS; EPITHELIUM; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTIC ACID; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES;

EID: 0042420739     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis. Adv Perit Dial 1997; 13: 17-22.
2. Gotloib L, Wajsbrot V, Shostack A, Kushnier R. Experimental approach to peritoneal morphology. Perit Dial Int 1994; 14(Suppl 3):S6-11.
3. Feriani M, Carobi C, La Greca G, Buoncristiani U, Passlick-Deetjen J. Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 1997; 17:17-21.
4. Coles GA, Gokal R, Ogg C, Jani F, O'Donoghue DT, Cancarinu GC, et al. A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int 1997; 17:48-51.
5. Capelli G, Bandiani G, Cancarini GC, Feriani M, Dell'Aquila R, Saffioti S, et al. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: prospective cross-over study with a three-compartment bag. Adv Perit Dial 1999; 15:238-42.
6. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
7. Pannekeet MM, Hiralall JK, Struijk DG, Krediet RK. Longitudinal follow-up of CA 125 in peritoneal effluent. Kidney Int 1997; 51:888-93.
8. Pannekeet MM, Koomen GCM, Struijk DG, Krediet RK. Dialysate CA125 in stable CAPD patients: no relation with transport parameters. Clin Nephrol 1995; 44: 248-54.
9. Visser CE, Brouwer-Steenbereg JJE, Betjes MGH, Koomen GCM, Beelen RHJ, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10:64-9.
10. Passadakis P, Panagoutsos S, Thodis E, Tsivara I, Sopassi F, Kartali S, et al. Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis. Adv Perit Dial 1999; 15:40-4.
11. Krediet RT, Pannekeet MM, Struijk DG. Preservation of peritoneal membrane function. Kidney Int Suppl 1996; 56:62-8.
12. Jimenez C, Díaz C, Selgas R, Bajo MA, del Peso G, Sánchez-Tornero JA, et al. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome. Adv Perit Dial 1999; 15:36-9.
13. Topley N, Krediet RT, Jones S, Faict D, Tranæus A, Holmes C, on behalf of the Bicarbonate/Lactate Study Group. Peritoneal dialysate CA125, hyaluronan (HA), TGFβ1, and procollagen I peptide (PICP) in a randomized controlled study of bicarbonate/lactate (B/L)-based CAPD solution [Abstract]. Perit Dial Int 2000; 20:150.
14. Heimbürger O, Rippe B, Christensson A, Haraldsson B, Simonsen O, Stelin G, et al. Dialysate CA125, hyaluronan (HA) and procollagen 1 peptide (PICP) in CAPD patients during 12 months treatment with a PD fluid containing less toxic glucose degradation products [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S80.
15. Simonsen O, Wieslander A, Landgren C, Rippe B. Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid. Adv Perit Dial 1996; 12:156-60.
16. Topley N, Coles GA, Williams JD. Biocompatibility studies on peritoneal cells. Perit Dial Int 1994; 14(Suppl 3): S21-8.
17. Lai KN, Lai KB, Szeto CC, Ho KKL, Poon P, Lam CWK, et al. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters. Am J Kidney Dis 1997; 29:699-705.
18. Sanusi AA, Zweers MM, Mateijsen MAM, Weening JJ, Struijk DG, Krediet RT. Is the expression of cancer antigen 125 (CA125) by peritoneal mesothelial cells (MCs) influenced by the duration of PD [Abstract]? Perit Dial Int 2000; 20(Suppl 1):S18.
19. Lage C, Pischetsrieder M, Aufricht C, Jörres A, Schilling H, Passlick-Deetjen J. First in vitro and in vivo experiences with Stay Safe Balance, a pH-neutral solution in a dual-chambered bag. Perit Dial Int 2000; 20(Suppl 5):S28-32.
20. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranæus A, et al., on behalf of the Bicarbonate/Lactate Study Group. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529-38.
21. Mackenzie RM, Lage C, Craig KJ, Williams JD, Schaub T, Passlick-Deetjen J, et al. European Balance Trial (EBT) Group. Continuous treatment with low GDP solution (CAPD Balance®) is associated with an increase in effluent CA125 and a decrease in HA content: data from the Multicenter European Balance Trial [Abstract]. Perit Dial Int 2002; 22:101.